TLR2 and TLR4 agonists trigger platelet activation in patients with AMI through NF-kappa B. Previous studies showed that the activation of TLR2 and TLR4 induced the innate immune response, increasing infarction size and influencing ventricular remodeling (31, 32). This evidence concerns the gene TLR4 and infarction.